Revenue
2025
Aspire Biopharma Holdings, Inc. (ASBP)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6,202 | — | — | — | — |
| Gross profit | −$116 | — | — | — | — |
| Research & development | $923,914 | $144,356 | — | — | — |
| Operating expenses | $19.4M | $1.2M | $1.3M | $976,345 | $25,475 |
| Operating income | −$19.4M | −$1.2M | — | — | — |
| Net income | −$24.5M | −$1.3M | $4.5M | $3.3M | −$25,475 |
| Diluted EPSper diluted share | -$16.38 | -$1.90 | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2025Form 4/A | Fell Donald G.Director | BuyCommon Stock, par value $0.0001 | 10.5K | $0.39 | $4.1K | 20.0K |
| Jun 5, 2025Form 4 | Fell Donald G.Director | BuyCommon Stock, par value $0.0001 | 10.5K | $0.39 | $4.1K | 20.0K |
| Jun 4, 2025Form 4/A | Fell Donald G.Director | BuyCommon Stock, par value $0.0001 | 9.5K | $0.39 | $3.7K | 9.5K |
| Jun 4, 2025Form 4 | Fell Donald G.Director | BuyCommon Stock, par value $0.0001 | 9.5K | $0.39 | $3.7K | 9.5K |